PRMT1 knockdown in tumor cells and macrophages in a diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) mouse model generated significant decreases in PD-L1 and PD-L2, resulting in reduced therapeutic efficacy of PD-1 antibody treatment (195). This evidence concerns the gene PRMT1 and hepatocellular carcinoma.